A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine

Launched by MERCK SHARP & DOHME LLC · Aug 30, 2001

Keywords

ClinConnect Summary

Patients are randomized to 1 of 4 treatment arms. In Group 1, patients receive a dose of L-756423/IDV once daily plus IDV placebo. In Group 3, patients receive a lower dose of L-756423/IDV twice daily (with the daily dosage equaling that of Group 1) plus IDV placebo. In Groups 2 and 4, patients receive equal dosages of IDV plus L-756423/IDV placebo. In all 4 groups L-756423 and IDV are blinded to the investigator and patient. All groups receive open-label d4T and 3TC. Patients routinely undergo a physical exam and have blood and urine tests to ensure the drugs' safety and tolerability, whic...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• You may be eligible for this trial if you:
• • Have HIV infection.
• • Have levels of CD4 cells of 100 cells/mm3 or greater.
• • Have a viral load of 10,000 copies/ml or greater.
• • Are 18 years of age or older.
• • Exclusion Criteria
• You may not be eligible for this trial if you:
• • Have ever taken anti-HIV drugs.